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ABSTRACT 32 
 33 
Genetic LCAT deficiency is a rare recessive autosomal disease due to loss-of-function mutations in 34 
the gene coding for the enzyme lecithin:cholesterol acyltransferase (LCAT). Homozygous carriers are 35 
characterized by corneal opacity, haemolytic anaemia and renal disease, which represent the first cause of 36 
morbidity and mortality in these subjects. Diagnostic and prognostic markers capable of early detecting 37 
declining kidney function in these subjects are not available, and the specific serum or urine proteomic 38 
signature of LCAT deficient carriers has never been assessed. Taking advantage of a proteomic approach, 39 
we performed 2-DE analysis of carriers’ plasma and identified proteins present at different concentration 40 
in samples from homozygous carriers. Our data confirm the well-known alterations in the concentration 41 
of circulating apolipoproteins, with a statistically significant decrease of both apoA-I and apoA-II and a 42 
statistically significant increase of apoC-III. Furthermore, we observed increased level of alpha-1-43 
antitrypsin, zinc-alpha-2-glycoprotein and retinol-binding protein 4, and reduced level of clusterin and 44 
haptoglobin. Interestingly, only beta but not alpha subunit of haptoglobin is significant reduced in 45 
homozygous subjects. 46 
Despite the limited sample size, our findings set the basis for assessing the identified protein in a 47 
larger population and for correlating their levels with clinical markers of renal function and anaemia. 48 
 49 
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 53 
Significance 54 
 55 
This investigation defines the effects of LCAT deficiency on the level of the major plasma proteins in 56 
homozygous and heterozygous carriers. Increase for some proteins, with different function, together with 57 
a drop for haptoglobin, and specifically for haptoglobin beta chains, are reported for the first time as part 58 
of a coherent signature. 59 
We are glad to have the opportunity to report our findings on this subject, which is one of the main 60 
interests for our research group, when Journal of Proteomics celebrates its 10th anniversary. With its 61 
various sections devoted to different areas of research, this journal is a privileged forum for publishing 62 
proteomic investigations without restrictions either in sample type or in technical approach. It is as well a 63 
privileged forum for reviewing literature data on various topics related to proteomics investigation, as 64 
colleagues in our research group have done over the years; by the way, a good share of the reviewed 65 
papers were as well reports published in Journal of Proteomics itself. The journal also offers 66 
opportunities for focused surveys through thematic issues devoted to a variety of subjects, timely selected 67 
for their current relevance in research; it was an honour for colleagues in our group to recently act as 68 
editors of one of those. Out of this diverse experience, we express our appreciation for the endeavour of 69 
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Journal of Proteomics in its first 10 years of life – and wish identical and possibly greater success for the 70 
time to come. 71 
 72 
 73 
Highlights 74 
 75 
• The plasma proteome of homozygous and heterozygous carriers of LCAT mutations were 76 
analysed. 77 
• Decreased levels of apolipoproteins vs control subjects could be confirmed. 78 
• The next most relevant change observed was a substantial drop in haptoglobin beta chains. 79 
• This finding correlates with altered membrane composition and stability, haemolysis and 80 
anaemia. 81 
• A few proteins, with diverse biological function, were found at increased levels in heterozygotes. 82 
  83 
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1. Introduction 84 
 85 
Human lecithin:cholesterol acyltransferase (LCAT) is a plasma glycoprotein responsible of the 86 
synthesis of most of the plasma cholesteryl esters (CE) in humans. LCAT plays a central role in the 87 
intravascular metabolism of high-density lipoprotein (HDL) and in the determination of the levels of 88 
cholesterol associated with them (HDL-C) [1]. Mutations in the LCAT gene cause two LCAT deficiency 89 
syndromes, classical familial LCAT deficiency (FLD, MIM# 245900) and fish-eye disease (FED, MIM# 90 
136120) [2]. The differential diagnosis of FLD and FED is based on stringent biochemical criteria and is 91 
restricted to homozygotes or compound heterozygotes for these mutations. FLD cases have a completely 92 
defective cholesterol esterification; as a result, there is very little CE in plasma, and unesterified 93 
cholesterol accumulates in all plasma lipoprotein fractions. In FED cases, LCAT does not esterify 94 
cholesterol in HDL, which represent the preferred substrate of the enzyme, but does it so in VLDL and 95 
LDL: as a result, CE are present in plasma if at much reduced levels [2]. 96 
Genetic LCAT deficiency is characterized by an abnormal plasma lipoprotein profile featuring a low 97 
HDL-C level, with mainly small discoidal pre-beta particles, together with the presence of LpX, an 98 
abnormal lipoprotein usually absent in plasma and detectable only in some pathological cases [3, 4]. 99 
Carriers also present with corneal opacity due to cholesterol accumulation, mild chronic normochromic 100 
anaemia, and renal disease. Renal disease, which ultimately progresses to end-stage renal disease, is the 101 
major cause of morbidity and mortality in LCAT-deficient carriers [2]. The dramatic alterations in 102 
lipoprotein profile, especially the presence of LpX, have been shown to be directly involved in the 103 
glomerulosclerosis development [5] but the cause of kidney failure in these subjects is poorly understood. 104 
No specific treatment for renal disease in LCAT deficiency is currently available, and carriers are 105 
usually treated symptomatically. The therapy of LCAT deficiency nephropathy mainly aims at delaying 106 
the evolution of chronic nephropathy on the basis of available therapies, such as changes in life style and 107 
diet and control of complications such as hypertension and proteinuria [2]. FLD patients are often treated 108 
by dialysis [6, 7]; they are candidates for renal transplantation, but the disease can rapidly reoccur in the 109 
transplanted tissues within a few years [8]. 110 
Not all carriers of LCAT mutations develop renal disease, and the rate of progression of renal disease 111 
is unpredictable, even within the same family; some patients rapidly worsen from a mild proteinuria to a 112 
rapid deterioration of their renal function [9]. Thus, there is the urgent need for specific diagnostic and 113 
prognostic markers, other than traditional measures of renal function, capable of detecting declining 114 
kidney function early in time in these individuals in order to address high-risk carriers toward preventive 115 
programs and potential therapies. 116 
In this context, proteomic provides useful information for the identification and characterization of 117 
alterations in plasma protein levels. Up to now no specific serum or urine proteomic signature of LCAT 118 
deficient carriers has been defined. In this work, we applied a proteomic approach to investigate the 119 
plasma pattern in homozygous and heterozygous carriers of LCAT deficiency, in comparison with the 120 
pattern of non-affected subjects. 121 
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 122 
2. Materials and Methods 123 
 124 
2.1. Subjects 125 
The investigation involved a total of 38 carriers of LCAT mutations, all FLD; 13 homozygotes and 25 126 
heterozygotes, and 23 non-affected family members (controls), all belonging to Italian LCAT-deficient 127 
families [9]. All of the subjects were fully informed of the modalities and end points of the study and 128 
signed an informed consent. Proteomic analysis of plasma was performed on samples from ten carriers, 129 
and eight age-matched controls. Five individuals were carriers of two mutant LCAT alleles (four 130 
homozygotes and one compound heterozygote, defined homozygotes throughout the paper), while five 131 
subjects were heterozygotes; all of them were diagnosed as FLD.  132 
Blood samples were collected, after an overnight fast, into tubes containing Na2-EDTA; plasma was 133 
prepared by low speed centrifugation at 4°C and stored in aliquots at -80°C until assayed. 134 
 135 
2.2. Biochemical analyses 136 
Plasma total and unesterified cholesterol, triglyceride and HDL-C levels were determined with 137 
standard enzymatic techniques; LDL-C was calculated with the Friedewald’s equation. Plasma 138 
apolipoprotein levels were measured by immunoturbidimetry on a Roche c311 autoanalyzer. The plasma 139 
preβ-HDL content, expressed as percentage of total plasma apolipoprotein A-I (apoA-I), was determined 140 
by native 2-DE, in which agarose gel electrophoresis was followed by nondenaturing gel gradient 141 
electrophoresis (GGE), and subsequent immunoblotting for apoA-I [10]. Plasma LCAT concentration 142 
was measured by an immunoenzymatic assay [11], and the esterification of cholesterol incorporated into 143 
an exogenous standardized substrate (LCAT activity) was measured as previously described [9]. Plasma 144 
haptoglobin levels were determined via enzyme-linked immunosorbent assay (ELISA) using the Human 145 
Haptoglobin Quantikine ELISA kit (catalogue #DHAPG0; R&D Systems, Inc., Minneapolis, USA) 146 
according to the manufacturer’s instructions. 147 
 148 
2.3. Electrophoretic procedures 149 
Two-dimensional electrophoresis (2-DE) maps were obtained using the immobilised pH gradient 150 
(IPG)–Dalt method, as previously described [12, 13]. Plasma (25 µL) was diluted with an equal volume 151 
of water and reduced with 2% 2-mercaptoethanol; each plasma sample was loaded at the cathodic end of 152 
one laboratory-made focusing strip. The proteins were first resolved according to charge on a non-linear 153 
pH 4-10 IPG [14] in the presence of 8 M urea and 0.5% carrier ampholytes with an anode-to-cathode 154 
distance of 8 cm. The focused proteins were then fractionated according to size by SDS-PAGE on 7.5-155 
17.5% polyacrylamide gradients on 160x140 mm2 SDS slabs using the discontinuous buffer system of 156 
Laemmli [15]. Finally, the proteins were stained with 0.3% (wt/vol) Coomassie.  157 
The scanned gel patterns were analysed with Image Master Software (Amersham Biosciences, ver. 5.0) 158 
and the spectrometry identification of proteins, whose spot volume (i.e., absorbance integrated over area) 159 
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was statistically different among the three groups of subjects, was made as previously described [16]. 160 
 161 
For haptoglobin phenotyping, equal volumes of human plasma were diluted in sample loading buffer 162 
(1:100) and analysed as previously described [17].  163 
Briefly, levels of haptoglobin subunits were evaluated in plasma diluted in sample loading buffer 164 
(1:100) (20 g/l sodium dodecyl sulfate, 100 ml/l glycerol, 25 mmol/l Tris [pH 6.8], 0.05 g/l bromophenol 165 
blue, 50 mmol/l dithiothreitol), and loaded on a 18% T polyacrylamide gel with Hp standards 1-1 and 2-2 166 
(Sigma-Aldrich, Milan, Italy). 167 
Immunoblotting was performed with a 1:10,000 dilution of polyclonal rabbit anti-human Hp (Sigma-168 
Aldrich) and a goat anti-rabbit immunoglobulin-G horseradish peroxidase conjugated (Bio-Rad 169 
Laboratories, Milan, Italy), diluted 1:10,000 in Tris-buffered saline and Tween 20 (TBST) as secondary 170 
antibody. The bands of alpha and beta subunits (~20 kDa and ~50 kDa, respectively) were detected by 171 
ECL and quantified by densitometry using an image analysis software (QuantityOne version 4.5.2; Bio-172 
Rad, Milan, Italy). For each subject, data are reported as the ratio of band volume, after local background 173 
subtraction, vs the volume of a normalising sample loaded in each gel, and are expressed in arbitrary units 174 
(AU). Inter-assay coefficient of variation was 12.1 ± 2.9 %. 175 
 176 
2.4. Statistical analyses 177 
Results are presented as mean±SD. The trends in plasma protein levels across genotypes were 178 
assessed by ANOVA; P values < 0.05 were considered as statistically significant. Statistical analysis was 179 
performed using SPSS version 24.0 software (SPSS Inc., Chicago, USA). 180 
 181 
3. Results 182 
 183 
3.1. Characteristics of the subjects 184 
Individuals from the previously reported Italian families with mutations in LCAT gene participated in 185 
the study [9]. Only few subjects were submitted to a detailed two-dimensional (2-DE) proteomic 186 
investigation: in particular we analysed 5 FLD homozygotes, 5 FLD heterozygotes and 8 non-affected 187 
family members who acted as controls. Carriers of LCAT gene mutations, as previously reported, have 188 
significantly reduced HDL-C, apoA-I, apoA-II levels, and LCAT mass, with a gene-dose dependent 189 
effect. LCAT activity, as expected, was null in homozygous subjects and significantly reduced in 190 
heterozygotes while triglyceride levels, unesterified cholesterol, unesterified/total cholesterol and preβ-191 
HDL were significantly increased (Table 1).  192 
 193 
3.2. 2-DE analyses  194 
The analysis of the plasma proteome of the three groups of subjects was carried out under reducing 195 
conditions with 1st dimension in the 4-10 pH range; Figure 1 shows the 2DE map of a control sample in 196 
the top panel and of a LCAT-deficient patient in the bottom panel. As expected, in most cases, we 197 
observed spot rows rather than single spots, each protein species [18] resulting from a specific set of post-198 
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translational modifications [19, 20]. When relevant, the statistic analysis on spot volumes was made both 199 
on the values of each individual spot and of the whole spot row. 200 
The proteins differing in volume in one or more spots, corresponding to one or more of their PTM-201 
species or of their proteolytic fragments, in a patients vs controls comparison, are outlined in the top 202 
panel; their numbering corresponds to that of the entries in Table 2 and in Supplementary Table 1, which 203 
contain the identifications made possible by MS analysis of the picked spots. Table 2 summarizes as well 204 
the significant changes in spot abundance pointed out by the statistical treatment of the 2-DE 205 
densitometric data. 206 
From the above comparison, significantly lower levels of apolipoprotein A-I and apolipoprotein A-II 207 
were highlighted, as expected, in homozygous subjects with respect to controls. In addition, in 208 
homozygotes, we found increased plasma levels of several proteins such as alpha-1-antitrypsin, zinc-209 
alpha-2-glycoprotein, retinol-binding protein 4 and transthyretin, and significantly lower levels of the beta 210 
chain of haptoglobin. 211 
 212 
3.3. Haptoglobin  213 
Plasma haptoglobin levels were measured in a larger group of subjects that included 13 FLD 214 
homozygotes, 25 FLD heterozygotes and 23 controls (Supplementary Table 2). Plasma protein 215 
concentration both in controls and in patients was within the reported reference range (32-205 mg/dL) 216 
and the ELISA measurement did not confirm the reduction of haptoglobin concentration in homozygous 217 
subjects, observed in 2-DE analysis. Indeed, carriers of LCAT gene mutations showed plasma haptoglobin 218 
levels comparable to controls (controls 74.0 ± 27.3 mg/dL; heterozygotes, 80.8 ± 35.7 mg/dL; 219 
homozygotes, 75.7 ± 65.2 mg/dL; P for trend  = 0.58). 220 
In order to find a rationale for the above discrepancy, we investigated by immunoblotting after 1-DE 221 
the abundance of the haptoglobin subunits (alpha and beta), characterized by different molecular weights. 222 
With this approach, we observed that homozygous subjects are characterized by a significant reduction of 223 
the beta subunit (homozygotes, 0.99 ± 0.38 AU; heterozygotes, 1.43 ± 0.14 AU; controls 1.44 ± 0.22 AU; 224 
P for trend = 0.016; Figure 2) but not of the alpha subunit. 225 
 226 
4. Discussion 227 
 228 
The proteomic investigation we describe in this report affords for the first time a comprehensive 229 
evaluation of all major plasma components in homozygous carriers of LCAT mutations that result in the 230 
virtual absence from the circulation of the enzyme in its active form [1]. 231 
 232 
Our data on homozygous carriers fully confirm the well-known alterations in the concentration of 233 
circulating apolipoproteins, with a statistically significant decrease of both apoA-I and apoA-II and a 234 
statistically significant increase of apoC-III [21]. The main interest, however, of our approach is the 235 
indication it provides for altered concentrations of serum components other than apolipoproteins and 236 
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related to clinical manifestations of the disease, which include anaemia and renal disease. Specifically 237 
haptoglobin and clusterin decrease, while alpha-1-antitrypsin, zinc-alpha-2-glycoprotein and retinol-238 
binding protein 4 increase in homozygous carriers. 239 
Haptoglobin concentration is influenced by diet, and specifically by amount and composition of 240 
dietary fat: it was found significantly up-regulated in animals receiving a high-fat, high-cholesterol chow 241 
[22] whereas it was significantly down-regulated in human volunteers receiving omega-3 242 
supplementation [23]. In more detail, haptoglobin is characterized by a molecular heterogeneity, which 243 
includes three major phenotypes: Hpt 1-1, Hpt 2-1 and Hpt 2-2. The various phenotypes perform 244 
differently in connection with lipid metabolism: when tested in in vitro and in vivo models of diabetes 245 
mellitus, reverse cholesterol transport appears much more reduced in Hp2-2 than in Hp1-1 mice [24]. The 246 
rationale for testing diabetic animals in the latter trial is that a differential prevalence of coronary heart 247 
disease – one of the sequels of altered cholesterol transport – is observed in human patients depending on 248 
haptoglobin phenotype, with opposite trend in diabetic (lower in 2-1) and in non-diabetic subjects (higher 249 
in 2-1) [25]. 250 
In our 2-DE experiments, a statistically significant decrease in homozygous vs control subjects is 251 
observed for as many as 6 spots identified as haptoglobin or better, from their position in the pI/Mr map, 252 
for haptoglobin beta chains. The finding was confirmed by an independent approach based on molecular 253 
recognition, namely immunoblotting after 1-DE separation of the proteins. On the contrary, ELISA does 254 
not distinguish the different haptoglobin subunits.  255 
The finding of reduced circulating haptoglobin is related to normochromic haemolytic anaemia 256 
detected in FLD subject. In erythrocytes, the increase in free cholesterol and phosphatidylcholine and the 257 
decrease in phosphatidylethanolamine affect membrane fluidity; the lysis of fragile cells eventually leads 258 
to normochromic normocytic anaemia; hemoglobin is released meanwhile [26-28]. Haptoglobin binds 259 
free hemoglobin and the complex is cleared from the circulation [29]. In connection with iron 260 
homeostasis, the 2-2 phenotype is associated with lower affinity for hemoglobin and lower antioxidant 261 
capacity, which results in higher sideraemia, higher ferritin and lower transferrin concentrations, and 262 
higher transferrin saturation than in the 1-1 and 2-1 phenotypes [30].  263 
The formation of the complex between hemoglobin and haptoglobin involves a direct contact between 264 
the alfa-beta protomer of the former and the beta chain of the latter. This was first deduced from binding 265 
experiments using either synthetic peptides [31, 32] or isolated whole subunits [33] and has been 266 
demonstrated in crystallographic experiments with both bovine [34] and human [35] proteins. It is not 267 
obvious to proceed from this evidence to our findings of a selective decrease of the circulating levels of 268 
just the beta subunits of haptoglobin, as we have evaluated both in the densitometric measurements on the 269 
spots resolved by electrophoresis and by immunoblotting. In fact, haptoglobin alpha and beta chain, 270 
bound to one another by disulfide bridges, result from the proteolytic cleavage of a single polypeptide 271 
transcript [36], which should ensure a stoichiometric synthesis. Also the mechanism of the clearance of 272 
the complex, requiring the internalization via the monocyte/macrophage scavenger receptor CD163 [37] 273 
and the transfer to early endosomes [38] implies the degradation to heme, bioactive peptides, and amino 274 
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acids, without any selectivity for either of the chain components. We could not find literature data about a 275 
varying effect on the different subunits of the condition we are considering here, hemolysis. However, 276 
Fernandez-Costa et al. report at least one example of uneven regulation of the haptoglobin chains [39]. 277 
By immunoblot on osteoarthritis patient’s sera, these authors detected an increase of the beta chain by 278 
2.22-fold vs control subjects; instead, the alpha chain increased only by 1.4-fold when in the 1 phenotype 279 
and decreased 0.7-fold when in the 2 phenotype. While without statistical significance per se the latter 280 
result was duplicated by quantitation through the multiple reaction monitoring technology (digestion, 281 
nanoHPLC, MS). 282 
 283 
Both haptoglobin and clusterin/apoJ, another protein changed in proteomic pattern of homozygous 284 
carriers, may be present in the circulation either in soluble form or associated with HDL. Actually, 285 
haptoglobin-related protein exists solely as a component of a minor subspecies of large high-density 286 
lipoproteins (HDL3) containing apolipoprotein L-I. Its assembly into the lipoprotein particle is mediated 287 
by the retained N-terminal signal peptide, an unusual feature for a secreted protein and the major 288 
difference between haptoglobin-related protein and haptoglobin. The 18-amino acid signal peptide 289 
interacts directly with the hydrocarbon region of lipids: lipid fluidity hastens the interaction while lipid 290 
rigidity stabilizes the association [40]. Haptoglobin is able as well to bind to lipoproteins through its 291 
interaction with apoA-I [41] and apoE [42]. 292 
 293 
Two of the three significantly increased protein in homozygous carriers, i.e. retinol-binding protein 4 294 
and zinc-alpha-2-glycoprotein have been described altered in chronic kidney diseases. 295 
Circulating retinol-binding protein 4 appears positively correlated with serum creatinine levels and 296 
inversely correlated with glomerular filtration rates [43-46]; no correlation is observed instead with 297 
another sign of glomerular dysfunction, microalbuminuria [43], or with a different type of long-term 298 
sequel of diabetes, atherosclerosis, as assessed by carotid intima-media thickness [45]. Plasma levels of 299 
retinol-binding protein 4 decrease after kidney transplantation to patients with end-stage renal disease 300 
[46]. In carriers of genetic LCAT deficiency retinol-binding protein 4 increases in plasma with a gene-301 
dose dependent effect. 302 
In patients with chronic kidney disease, plasma concentration of zinc-alpha-2-glycoprotein increases 303 
with the progression of the disease and the decline of glomerular filtration rate [47]. The observation that 304 
mice (-/-) for the corresponding gene develop significantly more kidney fibrosis in models of kidney and 305 
heart injury suggests that this protein exerts an antifibrotic effect that is duplicated in vitro by sera of 306 
patients with high levels of zinc-alpha-2-glycoprotein [48]. Zinc-alpha-2-glycoprotein is significantly 307 
increased in plasma of homozygous and compound heterozygous carriers of genetic LCAT deficiency. 308 
 309 
5. Conclusions 310 
 311 
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The concentration of any given protein at any given time in any given compartment results from the 312 
compound effects not only of synthesis and catabolism but also of distribution from/to any other 313 
compartment. The latter may be ruled solely by the physic-chemical properties of the protein or be 314 
mediated by its interaction with other proteins, to form assemblies in solution and/or receptor-ligand 315 
complexes at the cell surface. Examples of counterintuitive explanations for analytical findings are 316 
provided in routine clinical biochemistry tests by increase in circulating myoglobin due to decreased 317 
glomerular filtration and by decrease in C3 and/or C4 due to increased consumption after activation of the 318 
complement pathway(s). Changes in protein concentration independent from regulation of protein 319 
synthesis are observed also in the homozygous/doubly heterozygous carriers of LCAT mutations. 320 
A low-grade inflammatory condition is an expected outcome in the presence of reduced levels of 321 
apoA-I (some human data: [49, 50]; some animal data: [51, 52]). The observation of increased 322 
concentration for alpha-1-antitrypsin in the homozygous/doubly heterozygous carriers of LCAT 323 
mutations confirms the expectation for its increased synthesis in these subjects. Up-regulation is to be 324 
assumed as well for haptoglobin; the finding, instead, of a lower concentration in the carriers must be 325 
caused by the overlap with a process consuming haptoglobin. Such an interfering phenomenon is easily 326 
identified in the scavenging of hemoglobin as it leaks from erythrocytes; in turn, haemolysis is the known 327 
outcome of altered membrane lipid composition in the absence of LCAT activity.  328 
 329 
Despite the limited sample size, our finding poses the base to investigate the identified protein in a 330 
larger population and correlate them with clinical markers of the disease (renal function and anemia). 331 
 332 
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Table 1 342 
Demographic and lipid/lipoprotein profile of carriers of LCAT deficiency 343 
 344 
 Carriers of LCAT deficiency  P trend 
 Controls Heterozygote Homozygotes  
N 8 5 5  
Sex (m/f) 4/4 3/2 4/1  
Age (years) 36.4 ± 11.1 34.6 ± 12.5 34.2 ± 3.1 0.917 
Total Cholesterol (mg/dL) 180.1 ± 22.1 148.8 ± 34.1 195.4 ± 106.1 0.264 
Unesterified Cholesterol (mg/dL) 55.9 ± 7.3 50.0 ± 11.1 181.4 ± 92.4 0.006 
Unesterified/total Cholesterol 0.29 ± 0.02 0.34 ± 0.03 0.94 ± 0.06 <0.001 
LDL-Cholesterol (mg/dL) 100.7  ± 26.3 78.3 ± 26.7 132.3 ± 78.7 0.348 
HDL-Cholesterol (mg/dL) 63.9 ± 15.6 43.8 ± 19.6 9.0 ± 4.8 <0.001 
Triglycerides (mg/dL) 77.9 ± 45.1 142.0 ± 95.4 254.6 ± 150.4 0.05 
Apolipoprotein A-I (mg/dL) 125.4 ± 27.2 94.6 ± 22.1 39.8 ± 8.8 0.003 
Apolipoprotein A-II (mg/dL) 31.6 ± 6.4 28.0 ± 3.8 7.8 ± 4.4 <0.001 
Apolipoprotein B (mg/dL) 83.1 ± 18.2 82 ± 24.0 54.8 ± 25.0 0.113 
preβ-HDL (% of apoA-I) 12.8 ± 1.7 19.5 ± 3.1 44.8 ± 9.3 0.002 
LCAT mass (µg/mL) 5.2 ± 1.7 3.85 ± 1.26 1.55 ± 0.68 0.002 
LCAT activity (nmol/mL/h) 40.3 ± 7.4 16.8 ± 10.3 nd <0.001 
Data are reported as mean±SD. nd = not detectable  345 
 346 
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Table 2 347 
List of plasma proteins identified by MS differently expressed among groups of subjects 348 
 349 
Spot number Protein Uniprot accession #  Controls Heterozygotes  Homozygotes 
1 Alpha-1-antitrypsin P01009 1.20 ± 0.79  1.28 ± 0.54 2.19 ± 0.92* 
2 Zinc-alpha-2-glycoprotein P25311 0.51 ± 0.23 0.48 ± 0.18 1.05 ± 0.55*,§ 
3 Haptoglobin P00738 0.31 ± 0.16 0.22 ± 0.06 0.00 ± 0.00* 
4 Haptoglobin P00738 0.84 ± 0.34 0.58 ± 0.24 0.00 ± 0.00* 
5+6+7+8 Haptoglobin + Serum albumin P00738+P02768 5.37 ± 1.34 5.35 ± 0.77 3.18 ± 1.64
*,§ 
9 Complement C3 P01024 0.04 ± 0.08 0.36 ± 0.20# 0.00 ± 0.00§ 
10 Zinc-alpha-2-glycoprotein P25311 1.12 ± 0.31 1.14 ± 0.30 1.64 ± 0.72*,§ 
11 Zinc-alpha-2-glycoprotein  or Haptoglobin 
P25311  
or P00738 0.30 ± 0.10 0.32 ± 0.14 1.10 ± 1.14
*,§ 
12 Clusterin P10909 0.11 ± 0.04 0.13 ± 0.06 0.00 ± 0.00*,§ 
13 Apolipoprotein A-I P02647 0.19 ± 0.08 0.24 ± 0.17 0.00 ± 0.00§ 
14 Apolipoprotein A-I P02647 2.43 ± 0.83 2.00 ± 1.24 0.66 ± 0.68* 
15 Apolipoprotein A-I P02647 10.03 ± 2.88 14.11 ± 9.39 4.21 ± 1.74*,§ 
16 Apolipoprotein A-I P02647 0.67 ± 0.39 0.32 ± 0.19 1.17 ± 0.38§ 
17+18 Retinol-binding protein 4 P02753 0.94 ± 0.59 1.17 ± 0.92 2.17 ± 1.67* 
19 Transthyretin + Serum albumin P02766+P02768 0.02 ± 0.04 0.15 ± 0.10
# 0.00 ± 0.00 
20 Transthyretin P02766 0.38 ± 0.13 0.85 ± 0.38# 1.03 ± 0.40* 
21 Apolipoprotein A-II P02652 5.95 ± 2.25 5.76 ± 3.15 0.86 ± 0.47*,§ 
Relative abundances, evaluated with 2DE under reducing conditions, are expressed as percent spot volume ± SD. 350 
*P<0.05 Homozygotes vs controls; §P<0.05 Homozygotes vs heterozygotes; #P<0.05 Heterozygotes vs controls 351 
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Figures 352 
 353 
 354 
 355 
Fig. 1. 2DE map of plasma under reducing conditions: control sample in top panel, LCAT-deficient 356 
sample in bottom panel. The first dimension is on a 4-10 non linear IPG, and the second dimension is on 357 
polyacrylamide gradient gels (7.5-17.5%). Spots selected for MS analyses are highlighted, and the entry 358 
numbers refer to Table 2 and Supplementary Table 1. 359 
14 
 
 360 
 361 
Fig. 2. Plasma β-subunit levels of haptoglobin were evaluated by immunoblotting, in carriers of LCAT 362 
gene mutations (n=5) and in non-affected family members (n=8). A representative immunoblot is shown 363 
in the top panel: M lane contains Mr markers, Hpt 1-1 and 2-2 lanes contain commercial samples with the 364 
corresponding phenotypes. The top panel plots the quantitative data from densitometric analysis.  365 
 366 
 367 
 368 
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 486 
Addendum to Materials and Methods 487 
Mass spectrometry identification of proteins from 2-DE gels 488 
The gel pieces were firstly washed and destained with 25 mmol/L NH4HCO3 and 50% v/v acetonitrile 489 
(ACN) twice, then three times with 1:2 ACN/50 mmol/L NH4HCO3. Finally the gel pieces were 490 
dehydrated with ACN and dried in SpeedVac for about 20 minutes. 491 
Samples were removed from SpeedVac and trypsin (Promega, Milan, Italy) at 12 µg/ml in 50 mmol/L 492 
NH4HCO3 was added for 30 minutes in ice. After the trypsin absorption the gel pieces were completely 493 
covered with few microliters of 50 mmol/L NH4HCO3 and put overnight at 37°C. After incubation formic 494 
acid was added at a final concentration of 0.1% and the products were analyzed by mass spectrometry. 495 
The samples were analysed by means of LC-ESI-MS/MS, with the spectra being recorded by a hybrid 496 
quadrupole orthogonal acceleration time-of-flight (Q-Tof) mass spectrometer (SYNAPT-MS G1, Waters 497 
Corporation, Milford, MA, USA) equipped with a TRIZAIC source and connected to a nanoACQUITY 498 
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UPLC system. The samples were injected onto a TRIZAIC nanoTile (Waters Corporation, Milford, MA, 499 
USA), Acquity HSS T3, that integrates a trapping column (5 µm, 180 µm x 20 mm) for desalting and an 500 
analytical column (1.8 µm, 85 µm x 100 mm) for peptide separation with an high level of reproducibility 501 
of retention time. The elution was performed at a flow rate of 450 nl/min by increasing the organic 502 
solvent concentration from 3 to 40% B in 30 min, using 0.1% formic acid in water as reversed phase 503 
solvent A and 0.1% formic acid in ACN as reversed phase solvent B. The Tof analyzer was externally 504 
calibrated using [Glu1]-fibrinopeptide B from m/z 50 to 1990, and the data were post-acquisition lock-505 
mass corrected using the monoisotopic mass of the doubly charged precursor of [Glu1]-Fibrinopeptide B 506 
(m/z 785.8426) infused into the mass spectrometer at a flow rate of 100 nl/min through a NanoLockSpray 507 
interface using the auxiliary pump of a nanoACQUITY system. A survey scan over the m/z range of 350-508 
1990 was used to identify protonated peptides with charge states of 2, 3 or 4, which were automatically 509 
selected for data-dependent MS/MS analysis (MassLynx v 4.1 SCN833, Waters Corporation, Milford, 510 
MA, USA). All raw MS data were processed with ProteinLynx Global SERVER software (PLGS v 2.5.3, 511 
Waters Corporation, Milford, MA, USA) and the proteins were identified by correlating the interpreted 512 
spectra with entries in UniProt database.  513 
A UniProt database (release 2015-3; number of human sequence entries, 20199) was used for database 514 
searches of each run. Carbamidomethylation was considered as fixed modification and methionine 515 
oxidation as variable, one missed cleavage per peptide was allowed, and the mass tolerance window was 516 
set to 25 ppm for peptide precursors and 0.05 Da for fragments. In parallel, the spectra were also searched 517 
against Uniprot database using Mascot (Matrix Science, London, UK). Valid identification required two 518 
or more peptides independently matching the same protein sequence, with a significant peptide score 519 
(higher than the identity score from Mascot). 520 
  521 
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 522 
Supplementary Table 2 523 
Demographic and lipid/lipoprotein profile of carriers of LCAT deficiency used for serum haptoglobin 524 
determination by ELISA.  525 
  Carriers of LCAT deficiency  P trend 
 Controls Heterozygote Homozygotes  
N 23 25 13  
Sex (m/f) 9/14 13/12 10/3  
Age (years) 45.0 ± 26.1 50.5 ± 21.0 34.6 ± 11.2 0.109 
Total Cholesterol (mg/dL) 197.1 ± 43.3 167.2 ± 37.2 160.8 ± 83.5 0.071 
Unesterified Cholesterol (mg/dL) 54.3 ± 11.7 47.6 ± 12.5 143.9 ± 71.1 <0.001 
Unesterified/total Cholesterol 0.28 ± 0.04 0.29 ± 0.06 0.92 ± 0.11 <0.001 
LDL-Cholesterol (mg/dL) 117.8  ± 33.5 101.5 ± 32.5 95.0 ± 63.0 0.220 
HDL-Cholesterol (mg/dL) 60.5 ± 14.3 39.6 ± 12.3 7.8 ± 4.4 <0.001 
Triglycerides (mg/dL) 94.7 ± 50.6 132.6 ± 55.3 279.8 ± 198.6 <0.001 
Apolipoprotein A-I (mg/dL) 132.0 ± 27.7 103.6 ± 23.0 38.5 ± 9.4 <0.001 
Apolipoprotein A-II (mg/dL) 31.8 ± 6.6 30.4 ± 5.1 6.7 ± 3.7 <0.001 
Apolipoprotein B (mg/dL) 92.2 ± 25.3 93.6 ± 20.4 52.2 ± 30.9 <0.001 
preβ-HDL (% of apoA-I) 12.9 ± 2.9 18.8 ± 7.6 45.2 ± 10.8 <0.001 
LCAT mass (µg/mL) 5.0 ± 1.0 3.7 ± 1.4 1.5 ± 1.0 <0.001 
LCAT activity (nmol/mL/h) 41.1 ± 11.8 20.1 ± 12.3 nd <0.001 
Data are reported as mean±SD. nd = not detectable  526 	527 	528 
 529 
